Saturday 17 October 2026
Export INFU’s income statement to Excel — free account
InfuSystems Holdings, Inc.
INFU Healthcare Medical Devices
InfuSystems Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $143.4 million, up 6.36% from fiscal 2024. In the quarter to June 2026, revenue grew 2.59%, EPS grew 33.3%, free cash flow fell 66.5% and total debt fell 22.5%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
13.33
0.59
−4.24%
Follow INFU
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
22.98 | 24.29 | 28.03 | 39.85 |
+8 more quarters Free account |
P/S ratio |
1.35 | 1.31 | 1.29 | 1.50 | |
P/FCF ratio |
90.30 | 28.15 | 30.70 | 36.69 | |
P/Operating CF |
28.58 | 192.32 | 26.00 | 24.90 | |
P/B ratio |
3.27 | 3.18 | 3.23 | 3.81 | |
Price to Tangible BV |
3.96 | 3.86 | 3.96 | 4.73 | |
EV/Sales |
1.49 | 1.43 | 1.41 | 1.64 | |
EV/EBITDA |
8.02 | 7.80 | 7.98 | 9.54 | |
EV/Operating CF |
9.13 | 8.66 | 8.27 | 9.19 | |
EV/FCF |
99.44 | 30.82 | 33.45 | 40.18 | |
Quick Ratio |
1.84 | 1.52 | 1.29 | 1.35 | |
Current Ratio |
2.50 | 2.14 | 1.80 | 1.90 | |
Net Debt/EBITDA |
2.59 | 3.61 | 2.32 | 2.81 | |
Debt/Assets |
20.90% | 19.91% | 19.52% | 21.17% | |
Debt/Equity |
0.35 | 0.33 | 0.34 | 0.38 | |
Asset Turnover |
1.44 | 1.40 | 1.41 | 1.38 | |
Operating CF/Net income |
2.10 | 0.95 | 3.50 | 3.76 | |
Capex/Depreciation |
(1.34) | (0.38) | (0.65) | (0.08) | |
Interest Coverage |
16.28 | 6.24 | 14.28 | 11.55 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
46.74% | 53.71% | 46.15% | 46.62% | |
Intangible Assets out of Total Assets |
0.10 | 0.11 | 0.11 | 0.11 | |
Share Based Compensation of Revenue |
3.36% | 3.66% | 3.51% | 3.62% | |
Graham Net Nets |
0.00 | (0.02) | (0.04) | (0.04) | |
Graham Number |
5.28 | 4.99 | 4.47 | 3.99 | |
Earnings Yield |
4.35% | 4.12% | 3.57% | 2.51% | |
Free Cash Flow Yield |
1.11% | 3.55% | 3.26% | 2.73% | |
Revenue per Share |
1.84 | 1.67 | 1.75 | 1.79 | |
Operating CF per Share |
0.34 | 0.05 | 0.35 | 0.42 | |
Capex per Share |
(0.23) | (0.06) | (0.11) | (0.01) | |
Free Cash Flow per Share |
0.11 | (0.01) | 0.24 | 0.40 | |
Cash per Share |
0.05 | 0.10 | 0.15 | 0.05 | |
Shareholders Equity per Share |
2.95 | 2.91 | 2.78 | 2.72 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.95 | 2.91 | 2.78 | 2.72 | |
Free Cash Flow |
2.25 | (0.29) | 4.93 | 8.24 | |
Working Capital |
22.97 | 19.52 | 16.15 | 16.85 | |
Capital Expenditures |
(4.52) | (1.26) | (2.19) | (0.25) | |
Net Current Asset Value |
(0.28) | (3.25) | (6.90) | (7.84) | |
EV/EBIT |
16.08 | 15.84 | 16.94 | 21.40 | |
Capex to Sales |
0.12 | 0.04 | 0.06 | 0.01 | |
Price to Operating Income |
14.60 | 14.47 | 15.55 | 19.54 | |
| Other line items | |||||
Average Receivables |
25.84 | 23.94 | 22.03 | 23.54 | |
Average Payables |
9.15 | 9.00 | 10.33 | 9.47 | |
Average Inventory |
5.59 | 5.96 | 5.96 | 6.15 | |
Average Assets |
99.27 | 101.47 | 102.09 | 102.09 | |
Average Common Equity |
56.84 | 56.95 | 57.43 | 55.49 |
Columns are period end dates